Hangzhou Shimai

Hangzhou Shimai Pharmaceutical is a clinical-stage biopharmaceutical company based in China, specializing in the discovery and development of innovative antibody-based therapeutics. The company leverages its proprietary technology platforms, including the D-Mab bispecific antibody platform and the Hi-Mab fully human antibody library, to target complex diseases such as cancer and autoimmune disorders. Its pipeline features several bispecific and monoclonal antibodies currently in clinical and preclinical development, with a focus on next-generation immunotherapy. Hangzhou Shimai aims to address unmet medical needs through the development of high-affinity, low-toxicity biologics. The company's lead candidate, SMT-012, is a bispecific antibody targeting PD-L1 and TGF-beta, currently undergoing clinical trials for solid tumors.